92455-57-7

Upstream product

• 7733-29-1 Z-Orn(Boc)-OH 
• 100-39-0 benzyl bromide 
• 2640-58-6 Nα-benzyloxycarbonyl-L-ornithine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 98512-07-3 Z-Orn-OBn 
• 63446-55-9 N^δ-(Phosphonoacetyl)-L-orinithine 
• 92455-58-8 N^α-(Benzyloxycarbonyl)-N^δ-(dibenzylphosphonoacetyl)-L-ornithine benzyl ester 

Relevant academic research and scientific papers

NG-aminoguanidines from primary amines and the preparation of nitric oxide synthase inhibitors

A concise, general, and high-yielding method for the preparation of N G-aminoguanidines from primary amines is reported. Using available and readily prepared materials, primary amines are converted to protected N G-aminoguanidines in a one-pot procedure. The method has been successfully applied to a number of examples including the syntheses of four nitric oxide synthase (NOS) inhibitors. The inhibitors prepared were investigated as competitive inhibitors and as mechanistic inactivators of the inducible isoform of NOS (iNOS). In addition, one of the four inhibitors prepared, NG-amino-NG-2,2,2-trifluoroethyl-L-arginine 19, displays the unique ability to both inhibit NO formation and prevent NADPH consumption by iNOS without irreversible inactivation of the enzyme.

Synthesis and evaluation of peptidic maleimides as transglutaminase inhibitors

A series of novel transglutaminase inhibitors was prepared, based on the scaffold of a commonly used peptide substrate and bearing an electrophilic maleimide group. These compounds were evaluated in vitro and shown to lead to irreversible inactivation of tissue transglutaminase. Comparison with inhibitors studied previously provides insight into the steric environment of the enzyme active site.